Entera Bio (ENTX) lists CMO Riccardo Camisasca as reporting person

Rhea-AI Filing Summary

Entera Bio Ltd. (ENTX) reported an initial statement of beneficial ownership for Riccardo Paolo Camisasca, who serves as Chief Medical Officer. The Form 3 lists him as an officer but does not report any equity transactions, holdings tables, or derivative positions at this time.

Key Terms

Form 3, beneficial ownership, reporting person

3 terms

Form 3 regulatory

"reported an initial statement of beneficial ownership for Riccardo"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"reported an initial statement of beneficial ownership for Riccardo"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"The reporting person is Riccardo Paolo Camisasca, listed as an officer"

FAQ

What does this Form 3 filing mean for Entera Bio Ltd. (ENTX)?

The Form 3 identifies Riccardo Paolo Camisasca as a Chief Medical Officer and reporting person of Entera Bio Ltd. It is an initial statement of beneficial ownership and does not disclose any specific stock or option transactions or positions.

Who is the reporting person in this ENTX Form 3 filing?

The reporting person is Riccardo Paolo Camisasca, listed as an officer of Entera Bio Ltd. with the title Chief Medical Officer. He is not identified as a director or a ten percent owner in this filing.

Does the ENTX Form 3 report any stock purchases or sales?

No. The Form 3 includes no reported transactions. All buy, sell, acquire, dispose, and derivative transaction counts are shown as zero, and there are no holding entries or derivative positions listed.

Is Riccardo Paolo Camisasca a 10% owner of Entera Bio Ltd. (ENTX)?

According to the Form 3, Riccardo Paolo Camisasca is not a ten percent owner. He is flagged as an officer only, with no indication that he holds 10% or more of Entera Bio Ltd.’s equity securities.

Does the ENTX Form 3 mention a Rule 10b5-1 trading plan?

No. The document-level indicator for a Rule 10b5-1 plan is shown as null, and there are no transaction footnotes describing trades under such a plan, as no transactions are reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/21/2026 - 07:34 AM Accepted by SEC EDGAR 08/21/2026 - 07:34 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Camisasca Riccardo Paolo

(Last) (First) (Middle)

KIRYAT HADASSAH

MINRAV BUILDING, 5TH FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/18/2026

3. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Dana Yaacov-Garbeli, Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)